^
Association details:
| Biomarker: | BTK C481S |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | ABBV-101 (BTK degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1887 Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies
Published date:
11/02/2023
Excerpt:
ABBV-101 degrades BTK-WT and BTK-C481S with similar sub-nanomolar potency in the human DLBCL cell line TMD8 which translates to potent cellular growth inhibition...ABBV-101 induces complete tumor regression in the BTK-C481S TMD8 DLBCL xenograft model.
